keyboard_arrow_up

Worldide Hepatitis C Market Growth Report 2018

Global Hepatitis C Market 2014-2018 is the latest addition to Sandlerresearch.org industry research reports collection.


One of the emerging trends in the market is the emergence of Interferon -free regimens. Various IFN-free regimens are under development as all-oral regimens. These therapies are expected to attain higher SVR and cause fewer side effects than currently approved therapies.

The Report recognizes the following companies as the key players in the Global Hepatitis C Market: F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., Johnson & Johnson, Merck & Co. Inc. and Vertex Pharmaceuticals Inc.

Global Hepatitis C market to grow at a CAGR of 19.20 percent over the period 2013-2018

Other Prominent Vendors in the market are: AbbVie, Achillion Pharmaceuticals, Bristol-Myers Squibb, Mitsubishi Tanabe Pharma and Novartis.

Order a copy of this report at (Prices start at US $3000 for a single user PDF) http://www.sandlerresearch.org/purchase?rname=23004 .

According to the report, the launch of direct-acting antivirals is one of the major drivers of the market. These are administered in combination with other antiviral drugs such as ribavirin and PEG-IFN. They increase the efficacy of treatment and reduce the duration of therapy.

Further, the report states that the side effects of current therapies are one of the major challenges in the market. Currently, approved drugs for hepatitis C are associated with poor tolerability and lower patient compliance rates. This, in turn, decreases the market revenue of the currently approved drugs.

Table of Contents

01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
04. Market Research Methodology
05. Introduction
06. Disease Overview
07. Market Landscape
08. Key Marketed Drugs for Treatment of Chronic Hepatitis C
09. Market Segmentation by MOA
10. Geographical Segmentation
11. Buying Criteria
12. Market Growth Drivers
13. Drivers and their Impact
14. Market Challenges
15. Impact of Drivers and Challenges
16. Market Trends
17. Trends and their Impact
18. Vendor Landscape
20. Other Reports in this Series

List of Exhibits:

Exhibit 1: Market Research Methodology
Exhibit 2: Progression of Hepatitis C
Exhibit 3: Risk Factors for Hepatitis C Transmission
Exhibit 4: Prevalence Rates of Hepatitis C Across Different Geographies
Exhibit 5: Prevalence of Hepatitis C Genotypes in Tropical Latin America
Exhibit 6: Key Prevalence Data of Hepatitis C in East Asia and Pacific
Exhibit 7: Prevalence of Hepatitis C Genotypes in East Asia
Exhibit 8: Prevalence of Hepatitis C Genotypes in High Income Asia Pacific
Exhibit 9: Prevalence of Hepatitis C Genotypes in Australasia
Exhibit 10: Key Prevalence Data of Hepatitis C in Europe
Exhibit 11: Prevalence of Hepatitis C Genotypes in Eastern Europe
Exhibit 12: Prevalence of Hepatitis C Genotypes in Western Europe
Exhibit 13: Prevalence of Hepatitis C Genotypes in Central Europe
Exhibit 14: Key Prevalence Data of Hepatitis C in Latin America and Caribbean
Exhibit 15: Prevalence of Hepatitis C Genotypes in Tropical Latin America
Exhibit 16: Prevalence of Hepatitis C Genotypes in Andean Latin America
Exhibit 17: Prevalence of Hepatitis C Genotypes in Central Latin America
Exhibit 18: Prevalence of Hepatitis C Genotypes in South Latin America
Exhibit 19: Key Prevalence Data of Hepatitis C in Middle East and North Africa
Exhibit 20: Prevalence of Hepatitis C Genotypes in North Africa/Middle East